Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Other Income (Expense), Net
Interest income	$ 4,300,000	$ 6,500,000
Interest expense	(11,500,000)	(7,400,000)
Impairment of investments	(300,000)	(500,000)
Gain (loss) on sales of investments, net	4,400,000	11,800,000
Foreign exchange gains (losses), net	(2,600,000)	1,400,000
Other, net	(8,800,000)	3,300,000
Total other income (expense), net	(14,457,000)	15,144,000
Accrued Expenses and Other
Revenue-related rebates	204,000,000		191,000,000
Deferred revenue	157,100,000		148,000,000
Employee compensation and benefits	134,500,000		248,500,000
Collaboration expenses	56,700,000		37,400,000
Clinical development expenses	47,900,000		51,600,000
Royalties and licensing fees	42,800,000		45,200,000
Current portion of contingent consideration obligations	21,700,000		22,400,000
Other	220,400,000		235,800,000
Total accrued expenses and other	$ 885,093,000		$ 979,945,000